Skip to main content
Equibles
CDNA logo

CDNA · CareDx, Inc. · Metrics

Track CDNA — free

Use CDNA with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research CDNA.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$88.92 +3.04 (+3.54%) Q2 2026 earnings call transcript
Russell 2000 member Rebalance outlook locked
Market Cap
$4.51B
Shares
52.54M
Volume · Nov 3 1.59M Avg daily vol (3M) 1.3M

CDNA metrics

98 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$88.47
Market cap
$4.51B

Price action

20 metrics
Price change (1W)
+24.3%
Price change (30D)
+22.9%
Price change (3M)
+79.5%
Price change (6M)
+309.7%
Price change (YTD)
+355.8%
Price change (1Y)
+472.5%
Trailing year
Price change (5Y)
+74.4%
52-week high
$87.41
52-week low
$14.52
Change from 52-week high
-1.8%
Change from 52-week low
+491.5%
Annualized volatility
76.1%
Annualized volatility (3M)
64.7%
Beta
1.2
RSI (14D)
78.2
Price vs SMA 50
+41.5%
Price vs SMA 200
+152.8%
Avg volume (3M)
1.32M
Relative volume
1.8
Average dollar volume
$78.49M

Company

3 metrics
Sector
Healthcare
Industry
Diagnostics & Research
Shares outstanding
52.54M

Valuation

12 metrics
P / E (TTM)
35.9
Trailing earnings · reciprocal yield 2.8%
PEG ratio
0.0
EV / revenue
8.6×
reciprocal yield 11.7%
EV / EBITDA
31.7×
reciprocal yield 3.2%
EV / EBIT
36.6×
reciprocal yield 2.7%
P / sales
9.1×
reciprocal yield 11.0%
P / book
9.7
reciprocal yield 10.4%
FCF yield
—
TTM · current market cap
Buyback yield
0.5%
P / FCF
—
P / operating cash flow
65.4
reciprocal yield 1.5%
Earnings yield
2.9%

Historical valuation

8 metrics
P / E historical average (3Y)
18.5×
reciprocal yield 5.4%
P / E historical average (5Y)
18.5×
reciprocal yield 5.4%
EV / revenue historical average (3Y)
2.9×
reciprocal yield 35.1%
EV / revenue historical average (5Y)
2.9×
reciprocal yield 35.1%
EV / EBIT historical average (3Y)
16.9×
reciprocal yield 5.9%
EV / EBIT historical average (5Y)
16.9×
reciprocal yield 5.9%
EV / EBITDA historical average (3Y)
12.9×
reciprocal yield 7.8%
EV / EBITDA historical average (5Y)
12.9×
reciprocal yield 7.8%

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
0.5%
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-10-29

Profitability

9 metrics
Gross margin
—
Operating margin
23.4%
Trailing 12 months
Net margin
25.9%
Gross profit (TTM)
$98.19M
Operating profit (TTM)
$116.49M
Net income (TTM)
$128.63M
Trailing 12 months
Diluted EPS (TTM)
$2.39
FCF margin
—
Effective tax rate
-3.5%

Per share

11 metrics
Revenue per diluted share (TTM)
$9.39
Gross profit per diluted share (TTM)
$2.28
Operating profit per diluted share (TTM)
$2.17
EBITDA per diluted share (TTM)
$2.50
Net income per diluted share (TTM)
$2.39
Operating cash flow per diluted share (TTM)
$1.31
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
$1.60
Stock compensation per diluted share (TTM)
$0.72
Book value per share
$5.95

Growth

11 metrics
Revenue growth YoY
+39.3%
Year over year
Net income growth YoY
+1,051.8%
Revenue (TTM)
$497.40M
Trailing 12 months
EPS growth YoY
+1,066.7%
Shares change YoY
+2.3%
Year over year · more shares
Revenue CAGR (3Y)
+5.7%
Revenue CAGR (5Y)
+14.6%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
27.5%
Return on assets
20.1%
Debt / equity
0.0
Current ratio
2.3
EBITDA (TTM)
$134.29M
Free cash flow (TTM)
—
Quick ratio
2.2
Interest coverage
—
Net debt / EBITDA
-1.9
Return on invested capital
—
Trailing 12 months
Net cash
$250.48M
Latest balance sheet
Cash & equivalents
$250.48M
Total assets
$641.46M
Total debt
$0

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$69.02M
Capital expenditures (TTM)
$1.93M
R&D (TTM)
$84.42M
SG&A (TTM)
—
Stock compensation (TTM)
$38.20M
R&D / revenue
17.0%
Stock compensation / revenue
7.7%

Ownership (13F)

9 metrics
13F filers
228
13F filer change QoQ
+36
Institutional ownership
100.6%
Conviction holders (share of 13F filers)
1.8%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
+2.9%
Holder tenure
13.9
Price vs estimated holder cost
+58.1%

Ownership (registered funds)

1 metrics
Index-fund ownership
17.6%

Short interest

3 metrics
Short interest
12.8%
Latest settlement · 4.5 days to cover
Days to cover
4.5d
Short-squeeze score
91 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$1.05M
Insider-sentiment score
34 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1217234 CUSIP 14167L103 13F (30d) 63 filings 62 filers Visit website Investor relations